5-deazaflavin

Description

Deazaflavin : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	5376058
CHEMBL ID	1905125
SCHEMBL ID	5780165
CHEBI ID	4342
MeSH ID	M0071698

Synonyms (25)

Synonym
smr001570574
26908-38-3
nsc106042
mls002703860 ,
nsc-106042
deazaflavin
5-deazaflavin
C01800
1h-pyrimido[4,5-b]quinoline-2,4-dione
pyrimido(4,5-b)quinoline-2,4(1h,3h)-dione
unii-k2cc2rhc84
nsc 106042
k2cc2rhc84 ,
pyrimido[4,5-b]quinoline-2,4(1h,3h)-dione
chebi:4342 ,
CHEMBL1905125
SCHEMBL5780165
KWHWFTSHDPJOTG-UHFFFAOYSA-N
DTXSID10181415
pyrimido[4,5-b]quinolin-2,4(3h,10h)-dione
Q27106341
BBA90838
1h,2h,3h,4h-pyrimido[4,5-b]quinoline-2,4-dione
CS-0235609
EN300-1589278

Drug Classes (1)

Class	Description
pyridopyrimidine	Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.

Protein Targets (8)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
acid sphingomyelinase	Homo sapiens (human)	Potency	25.1189	AID504937
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	79.4328	AID588456
ClpP	Bacillus subtilis	Potency	3.5481	AID651965
Smad3	Homo sapiens (human)	Potency	12.5893	AID588855
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	AID540317
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	43.5774	AID540253; AID540263
snurportin-1	Homo sapiens (human)	Potency	43.5774	AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	16.3601	AID540253

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID1122999	Antiallergic activity in Wistar Charles River rat assessed as inhibition of histamine-induced passive cutaneous anaphylaxis at 3 mg/kg, iv relative to control	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1 ISSN: 0022-2623	Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.

Research

Studies (44)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (27.27)	18.7374
1990's	9 (20.45)	18.2507
2000's	8 (18.18)	29.6817
2010's	12 (27.27)	24.3611
2020's	3 (6.82)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (6.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	42 (93.33%)	84.16%

Substance	Classes	Roles	Relationship Strength
pd 173074	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	low
pd 158780	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
pipemidic acid	amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor	low
piromidic acid	monocarboxylic acid; pyridopyrimidine; pyrrolidines; quinolone antibiotic; tertiary amino compound	antibacterial drug; DNA synthesis inhibitor	low
risperidone	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist	low
trequinsin	pyridopyrimidine		low
pemirolast	pyridopyrimidine		low
ocaperidone	pyridopyrimidine		low
probon	pyridopyrimidine		low
8-methyl-4-oxo-3-pyrido[1,2-a]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
paliperidone	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol		low
pd 173955	aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine	tyrosine kinase inhibitor	low
2-imino-N,8-dimethyl-5-oxo-1-propan-2-yl-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
3-(benzenesulfonyl)-2-imino-1-(2-oxolanylmethyl)-5-dipyrido[1,2-d-3',4'-f]pyrimidinone	pyridopyrimidine		low
N-ethyl-2-imino-10-methyl-1-[(4-methylphenyl)methyl]-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
9,10-dimethoxy-2-(2-pyridinylmethylamino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one	pyridopyrimidine		low
LSM-33283	pyridopyrimidine		low
LSM-20487	pyridopyrimidine		low
LSM-31933	pyridopyrimidine		low
N-cyclopentyl-2-imino-1-[3-(4-morpholinyl)propyl]-5-oxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
LSM-28559	pyridopyrimidine		low
N-(2-furanylmethyl)-2-imino-5-oxo-1-(2-phenylethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
2-imino-10-methyl-N-[2-(4-morpholinyl)ethyl]-5-oxo-1-(3-pyridinylmethyl)-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
3-(benzenesulfonyl)-2-imino-1-propyl-5-dipyrido[1,2-d-3',4'-f]pyrimidinone	pyridopyrimidine		low
7-methyl-4-oxo-2-[(phenylmethyl)amino]-3-pyrido[1,2-a]pyrimidinecarboxaldehyde	pyridopyrimidine		low
6-propan-2-yl-2-sulfanylidene-1,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one	pyridopyrimidine		low
2-[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]-oxomethyl]imino-1-(2-methylpropyl)-5-oxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
LSM-26967	pyridopyrimidine		low
2-[2-furanyl(oxo)methyl]imino-5-oxo-1-propan-2-yl-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
1-(2-methoxyethyl)-7-thiophen-2-yl-5-(trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4-dione	pyridopyrimidine		low
1-butyl-2,4-dioxo-7-thiophen-2-yl-5-pyrido[2,3-d]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
1-cyclopentyl-2-imino-10-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
2-methyl-1-cyclopropanecarboxylic acid (7-bromo-4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl ester	pyridopyrimidine		low
2-imino-1-[(4-methylphenyl)methyl]-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
2-(3-ethoxypropylamino)-8-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[1,2-pyrimidinecarboxamide	pyridopyrimidine		low
3-[2,4-dioxo-1-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-quinazolinyl]-N-(2-furanylmethyl)propanamide	pyridopyrimidine		low
2-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methylthio]-3-pyridinecarboxylic acid propan-2-yl ester	isopropyl ester; pyridopyrimidine		low
2-chloro-6-[4-morpholinyl(oxo)methyl]-11-pyrido[2,1-b]quinazolinone	pyridopyrimidine		low
N-(2-furanylmethyl)-1-[2-(2-hydroxyethoxy)ethyl]-2-imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
1-(3-ethoxypropyl)-2-[2-furanyl(oxo)methyl]imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
1-butyl-2-[2-furanyl(oxo)methyl]imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
2-benzoylimino-1-(2-furanylmethyl)-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
6-[4-oxo-2-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methylthio]-3-thieno[3,2-d]pyrimidinyl]hexanoic acid	pyridopyrimidine		low
3-[4-oxo-2-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methylthio]-3-thieno[3,2-d]pyrimidinyl]propanoic acid	pyridopyrimidine		low
2-chloro-8-[4-morpholinyl(oxo)methyl]-11-pyrido[2,1-b]quinazolinone	pyridopyrimidine		low
3-(3,4-dimethylphenyl)sulfonyl-2-imino-1-prop-2-enyl-5-dipyrido[1,2-e-4',3'-f]pyrimidinone	pyridopyrimidine		low
1-[2-(3,4-dimethoxyphenyl)ethyl]-2-imino-10-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
3-(4-fluorophenyl)sulfonyl-1-(2-furanylmethyl)-2-imino-10-methyl-5-dipyrido[3,4-c-1',2'-f]pyrimidinone	pyridopyrimidine		low
LSM-27960	pyridopyrimidine		low
1-[(7-chloro-4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-(3-fluoro-4-methylphenyl)thieno[3,2-d]pyrimidine-2,4-dione	pyridopyrimidine		low
LSM-16446	pyridopyrimidine		low
2-bromo-6-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-11-pyrido[2,1-b]quinazolinone	pyridopyrimidine		low
LSM-16483	pyridopyrimidine		low
5-[[2-(diethylamino)-9-methyl-4-oxo-3-pyrido[1,2-a]pyrimidinyl]methylidene]-1,3-diazinane-2,4,6-trione	pyridopyrimidine		low
LSM-28172	pyridopyrimidine		low
3-ethyl-2-sulfanylidene-6,7,8,9-tetrahydro-1H-pyrimido[4,5-b]quinolin-4-one	pyridopyrimidine		low
8-(1-piperidinylsulfonyl)-6-pyrido[1,2-a]quinazolinone	pyridopyrimidine		low
pd 166866	biaryl; dimethoxybenzene; primary arylamine; pyridopyrimidine; ureas	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
palbociclib	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
gw2974	pyridopyrimidine		low
1-(3,4-dimethylphenyl)-2,5-dioxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarbonitrile	pyridopyrimidine		low
paliperidone palmitate	1,2-benzoxazoles; fatty acid ester; heteroarylpiperidine; organofluorine compound; pyridopyrimidine		low
ssr 69071	pyridopyrimidine		low
tgx 221	pyridopyrimidine		low
trametinib	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	low
pamapimod	aromatic amine; aromatic ether; difluorobenzene; diol; primary alcohol; pyridopyrimidine; secondary amino compound	antirheumatic drug; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
2-imino-8-methyl-5-oxo-1-(2-oxolanylmethyl)-N-(2-phenylethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
ku 0063794	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor	low
3-[(3-chlorophenyl)methyl]-5-ethoxy-1,6-dimethylpyrido[2,3-d]pyrimidine-2,4-dione	pyridopyrimidine		low
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor	low
kin-193	pyridopyrimidine		low
ly3009120	aminotoluene; aromatic amine; biaryl; monofluorobenzenes; phenylureas; pyridopyrimidine; secondary amino compound	antineoplastic agent; apoptosis inducer; autophagy inducer; B-Raf inhibitor; necroptosis inhibitor	low
sotorasib	acrylamides; methylpyridines; monofluorobenzenes; N-acylpiperazine; phenols; pyridopyrimidine; tertiary amino compound; tertiary carboxamide	antineoplastic agent	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	pre-1990
cromolyn sodium	1	organic sodium salt	anti-asthmatic drug; drug allergen	1979	1979	45.0	low	1
nivimedone	1			1979	1979	45.0	medium	1
proxicromil	1			1979	1979	45.0	low	1
6-ethyl-3-(1h-tetrazol-5-yl)chromone	1			1979	1979	45.0	medium	1
zaprinast	1	triazolopyrimidines		1979	1979	45.0	low	1

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	pre-1990	1990's	2000's	2010's	post-2020
formic acid	1	monocarboxylic acid	antibacterial agent; astringent; metabolite; protic solvent; solvent	1984	1984	40.0	low	1	0	0	0	0
ethanolamine	1	ethanolamines; primary alcohol; primary amine	Escherichia coli metabolite; human metabolite; mouse metabolite	2023	2023	1.0	low	0	0	0	0	1
glycine	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical	1995	1995	29.0	low	0	1	0	0	0
naphthalene	1	naphthalenes; ortho-fused bicyclic arene	apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component	2022	2022	2.0	low	0	0	0	0	1
nitrates	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species		2001	2001	23.0	low	0	0	1	0	0
oxalic acid	1	alpha,omega-dicarboxylic acid	algal metabolite; human metabolite; plant metabolite	1989	1989	35.0	low	1	0	0	0	0
4-hydroxyphenylpyruvic acid	1	2-oxo monocarboxylic acid; phenols	human metabolite	1992	1992	32.0	low	0	1	0	0	0
thymine	2	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite	1986	1993	34.5	low	1	1	0	0	0
nitroglycerin	1	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic	2001	2001	23.0	low	0	0	1	0	0
glutamine	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	2019	2019	5.0	low	0	0	0	1	0
uridine	1	uridines	drug metabolite; fundamental metabolite; human metabolite	1992	1992	32.0	low	0	1	0	0	0
tyrosine	2	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical	1984	1992	36.0	low	1	1	0	0	0
methionine	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical	1984	1984	40.0	low	1	0	0	0	0
phenylalanine	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite	1984	1984	40.0	low	1	0	0	0	0
pyrroles	1	pyrrole; secondary amine		1998	1998	26.0	low	0	1	0	0	0
cyclopentane	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent	1984	1984	40.0	low	1	0	0	0	0
oxazoles	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene		2012	2012	12.0	low	0	0	0	1	0
azomycin	2	C-nitro compound; imidazoles	antitubercular agent	2012	2012	12.0	low	0	0	0	2	0
propylene glycol dinitrate	1			2001	2001	23.0	low	0	0	1	0	0
magnesium perchlorate	1	alkaline earth salt		1993	1993	31.0	low	0	1	0	0	0
3-chloroperbenzoic acid	1	monochlorobenzenes; peroxy acid		1981	1981	43.0	low	1	0	0	0	0
n,n-dimethylthymine	2			1986	1993	34.5	medium	1	1	0	0	0
pyrimidine dimers	2			1986	1993	34.5	low	1	1	0	0	0
cyclopropanol	1	aliphatic alcohol; cyclopropanes		1985	1985	39.0	low	1	0	0	0	0
coenzyme f420	2			1984	2017	23.5	low	1	0	0	1	0
5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione	1	aminouracil; hydroxypyrimidine	Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	1992	1992	32.0	medium	0	1	0	0	0
1,5-dihydro-fad	1	flavin adenine dinucleotide	Escherichia coli metabolite; mouse metabolite	1992	1992	32.0	low	0	1	0	0	0
pa 824	1			2012	2012	12.0	low	0	0	0	1	0
riboflavin	6	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite	1984	2017	23.5	medium	1	2	1	2	0
flavin-adenine dinucleotide	1	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group	1992	1992	32.0	low	0	1	0	0	0
nadp	1			1984	1984	40.0	low	1	0	0	0	0
cysteine	1	cysteinium	fundamental metabolite	2019	2019	5.0	low	0	0	0	1	0
oxalates	1			1989	1989	35.0	low	1	0	0	0	0
opc-67683	1	piperidines		2012	2012	12.0	low	0	0	0	1	0
oligonucleotides	2			1993	2002	26.5	low	0	1	1	0	0
flavin mononucleotide	1			2019	2019	5.0	low	0	0	0	1	0
deoxyguanosine	1	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	1999	1999	25.0	low	0	1	0	0	0
guanine	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	1984	1984	40.0	low	1	0	0	0	0
8-hydroxy-2'-deoxyguanosine	1	guanosines	biomarker	1999	1999	25.0	low	0	1	0	0	0
factor 420	1			2016	2016	8.0	low	0	0	0	1	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	1990's	2000's	2010's
Infections, Mycobacterium	1	2016	2016	8.0	medium	0	0	1
Inflammation	1	2010	2010	14.0	medium	0	1	0
Innate Inflammatory Response	1	2010	2010	14.0	medium	0	1	0
Leukemia L 1210	1	1998	1998	26.0	medium	1	0	0
Leukemia, Lymphocytic	1	2008	2008	16.0	medium	0	1	0
Leukemia, Lymphoid	1	2008	2008	16.0	medium	0	1	0
Mycobacterium Infections	1	2016	2016	8.0	medium	0	0	1
Sensitivity and Specificity	1	2007	2007	17.0	medium	0	1	0

5-deazaflavin

Description

Cross-References

Synonyms (25)

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Bioassays (6)

Research

Studies (44)

Study Types

Related Drugs (118)

Drugs in this Class (73)

Drugs Involved in Assays Together (5)

Drugs Researched Together (40)

Related Conditions (8)